Beyond statins: new lipid lowering strategies to reduce cardiovascular risk (Q38207925)

31 August 2017

title

Beyond statins: new lipid lowering strategies to reduce cardiovascular risk (English)

1 reference

31 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24777633%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Maurizio Averna

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24777633%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Angelo B Cefalù

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24777633%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

1 June 2014

1 reference

Current Atherosclerosis Reports

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24777633%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24777633%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24777633%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

414

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24777633%20AND%20SRC:MED&resulttype=core&format=json

Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Antisense technologies. Improvement through novel chemical modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Molecular diagnosis of hypobetalipoproteinemia: an ENID review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

HDL-C: role as a risk modifier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Novel mutations of CETP gene in Italian subjects with hyperalphalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Safety of anacetrapib in patients with or at high risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0414-4

Rate of cholesteryl ester transfer between high and low density lipoproteins in human serum and a case with decreased transfer rate in association with hyperalphalipoproteinemia

21 January 2018

1 reference

12 December 2020

Design and synthesis of truncated EGF-A peptides that restore LDL-R recycling in the presence of PCSK9 in vitro

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy

1 reference

12 December 2020

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

1 reference

12 December 2020

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia

1 reference

12 December 2020

Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions

1 reference

12 December 2020

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, [...]

1 reference

12 December 2020

Plasma very low density lipoproteins contain a single molecule of apolipoprotein B

1 reference

12 December 2020

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

1 reference

12 December 2020

10.1007/S11883-014-0414-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24777633%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

1 June 2020

1045967970

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24777633%20AND%20SRC:MED&resulttype=core&format=json